Reduced-Intensity Conditioning and Allogeneic Transplant for Relapsed/Refractory HL in the Brentuximab Vedotin Era


Reduced-Intensity Conditioning and Allogeneic Transplant for Relapsed/Refractory HL in the Brentuximab Vedotin Era
Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with Christopher Flowers, MD, MS (2/24/14)
Anderlini P et al. Reduced-intensity conditioning (RIC) and allogeneic stem cell transplantation (allo-SCT) for relapsed/refractory Hodgkin lymphoma (HL) in the brentuximab vedotin era: Favorable overall and progression-free survival (OS/PFS) with low transplant-related mortality (TRM). Proc ASH 2013;Abstract 410.

Dr Flowers is Associate Professor of Hematology and Medical Oncology at Emory School of Medicine Winship Cancer Institute in Atlanta, Georgia.